CD19 and hematologic disorder: The high curative potential against hematologic malignancies afforded by CAR T cells support the large number of clinical trials targeting these entities (36 out of 62 trials retrieved at www.clinicaltrials.gov by using the following key words: “Chimeric Antigen Receptor”, “CAR”, “T-Body” and “Designer T cells”), and in particular those expressing the CD19 antigen (29/36).